ストックスクリーナーアプリを入手
2.43
2.10%
0.05
前日終値:
$2.38
開ける：
$2.46
24時間の取引高:
19,462
Relative Volume:
0.98
時価総額：
$26.93M
収益：
-
当期純損益:
$-3.15M
株価収益率:
-7.962
EPS:
-0.3052
ネットキャッシュフロー:
$-2.23M
1週間 パフォーマンス:
+1.28%
1か月 パフォーマンス:
+8.00%
6か月 パフォーマンス:
+9.18%
1年 パフォーマンス:
+15.17%
1日の値動き範囲:
$2.35
$2.56
1週間の範囲:
$2.18
$2.56
52週間の値動き範囲:
$1.20
$4.0499
Cytomed Therapeutics Ltd Stock (GDTC) Company Profile
GDTC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GDTC
Cytomed Therapeutics Ltd
|
2.43 | 26.93M | 0 | -3.15M | -2.23M | -0.3052 |
|
VRTX
Vertex Pharmaceuticals Inc
|
505.62 | 126.09B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.49 | 64.01B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
643.82 | 36.63B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
260.37 | 30.64B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.28 | 27.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytomed Therapeutics Ltd (GDTC) 最新ニュース
CytoMed 2024 Results: 39% Lower Losses as Biotech Advances Novel Cancer Cell Therapy Trial - Stock Titan
CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration - ACCESS Newswire
CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders - Marketscreener.com
SunAct Cancer Institute and CytoMed begin phase 2 trials for Gamma Delta T-cell therapy - Express Healthcare
CytoMed Therapeutics (NASDAQ:GDTC) Shares Down 13.7% – Here’s What Happened - Defense World
CytoMed and SunAct Collaborate on Cancer Immunotherapy Trials in India - Yahoo Finance
CytoMed Therapeutics and SunAct to conduct solid tumour treatment trial in India - Yahoo Finance
Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor - Benzinga
CytoMed Therapeutics Limited Signs Business & Research Collaboration Agreement with Sunact Cancer Institute Private Limited to Advance Use of Allogeneic Off-The-Shelf Gamma Delta T Cells for Treatment of Solid Cancers in Proposed Phase 2 Clinical Tr - Marketscreener.com
CytoMed and SunAct partner for cancer immunotherapy trials - Investing.com
CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in - Marketscreener.com
CytoMed Therapeutics Leads 3 US Penny Stocks To Consider - Simply Wall St
CytoMed Therapeutics Limited Announces Resignation of Dr Tan Wee Kiat as Co-Chief Executive Officer, Effective December 31, 2024 - Marketscreener.com
CytoMed Therapeutics Limited Announces Resignation of Dr Tan Wee Kiat as Director and Chief Operating Officer, Effective December 31, 2024 - Marketscreener.com
CytoMed Therapeutics : Organisation and personnel changes Form 6 K - Marketscreener.com
CytoMed Therapeutics And 2 Other US Penny Stocks To Watch - Simply Wall St
CytoMed Therapeutics : Update on Clinical Milestone CytoMed Therapeutics Announces First Patient Dosed in its First in Human Phase I Clinical Trial of Allogeneic CAR Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematologica - Marketscreener.com
CytoMed Therapeutics Limited Announces First Patient Dosed in Its First-In-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies - Marketscreener.com
Update on Clinical MilestoneCytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies - Yahoo Finance
Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap - Simply Wall St
Osteopore partners with NASDAQ-listed CytoMed to advance MSC-powered regeneration - Biotech Dispatch
Osteopore Partners with CytoMed in Regenerative Medicine - TipRanks
Cytomed Therapeutics announces NMRC co-funding support for ANGELICA trial - TipRanks
CytoMed Launches Innovative CAR-T Cell Trial - TipRanks
CytoMed begins clinical trial for innovative cancer therapy By Investing.com - Investing.com UK
CytoMed Therapeutics completes cash acquisition of Cord - GlobeNewswire
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 - GlobeNewswire
Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now - GlobeNewswire
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers - GlobeNewswire
Emergence of Cell and Gene Therapy Community in Singapore - BSA bureau
Navigating the Challenges Facing an Aging Global Population: How CytoMed Seeks to Help Boost Cartilage Regeneration | Value Investing NewsInvestor powered stock market news - Financial Content
CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair - GlobeNewswire
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology - Yahoo Finance
GDTC Stock Price and Chart — NASDAQ:GDTC - TradingView
Singapore-China collaboration to explore allogeneic gamma delta T cell technology for cancer treatment - BioSpectrum Asia
CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update - PR Newswire
CytoMed Expands Research Collaboration into China After Entering Into MOU - StreetInsider
CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo Persistency - PR Newswire
CytoMed Therapeutics Granted Patent in China for Licensed Allogeneic CAR-Gamma Delta T Cell Technology - Investing.com South Africa
CytoMed Therapeutics to Ring Nasdaq Closing Bell - Stock Titan
CytoMed and MD Anderson partner to use gdTc for cancer treatment - Pharmaceutical Technology
Cytomed squeaks out $9.6M in a near-frozen IPO market - BioWorld MedTech
Peter Choo-backed biomed firm CytoMed lists on Nasdaq - The Edge Singapore
GDTCCytoMed Therapeutics Ltd Latest Stock News & Market Updates - Stock Titan
CytoMed Therapeutics Limited Announces Pricing of Initial Public Offering - PR Newswire
IPO Update: CytoMed Therapeutics Aims For $11 Million U.S. IPO (Pending:GDTC) - Seeking Alpha
CytoMed Therapeutics (NASDAQ:GDTC) Stock Quotes, Forecast and News Summary - Benzinga
Malaysia-Singapore Collaborates In The Field Of Clinical Research - BusinessToday
Compulsory vaccination: MOH prepared to hear views from all - theSun
Biotech & Pharma News, Stocks, FDA Decision, Clinical Trials - RTTNews
Cytomed Therapeutics Ltd (GDTC) 財務データ
収益
当期純利益
現金流量
EPS
1.91%
0.28%
大文字化:
|
ボリューム (24 時間):